Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 7/Signature 1
From BugSigDB
Source: Text: Page 6 Paragraph 2
Description: A subset of the IBD patients receiving biologic therapy needed further treatment escalation to a second class of biologics. These patients had a significantly lower abundance of Bifidobacterium bifidum, Roseburia hominis and Bacteroides xylanisolvens compared to the IBD patients who received one biologic or conventional therapy.
Abundance in Group 1: decreased abundance in Inflammatory bowel disease patients receiving second class of biologic drug
| NCBI | Quality Control | Links |
|---|---|---|
| Bifidobacterium bifidum | ||
| Roseburia hominis | ||
| Bacteroides xylanisolvens |
Revision editor(s): Yjung24
